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a  b  s  t  r  a  c  totavirus  vaccines  are  being  introduced  in  several  low-  and  middle-income  countries  across  the  world  with  and  without  support  from  the  GAVI  Alliance.
ndia  has  the highest  disease  burden  of  rotavirus  based  on  morbidity  and  mortality  estimates  and  several  indigenous  vaccine  manufacturers  are developing
otavirus  vaccines.  One  candidate  has  undergone  phase  III  testing  and  others  have  completed  evaluation  in  phase  II. Global  data  on  licensed vaccine
erformance  in  terms  of impact  on  disease,  strain  diversity,  safety  and  cost-effectiveness  has  been  reviewed  to  provide  a framework  for decision  making
n India.
he  CC© 2014 Published  by  Elsevier  Ltd.  This  is an  open  access  article  under  t
. Introduction
Two live, attenuated, orally administered rotavirus vaccines
 a monovalent human rotavirus vaccine (RV1; RotarixTM (GSK
iologicals, Rixensart, Belgium)) and a pentavalent bovine-human
eassortant vaccine (RV5; RotaTeq® (Merck and Co, Inc, Pennsylva-
ia)) – are licensed for use in more than 100 countries worldwide,
ncluding India [1,2]. Promising clinical trial data from the United
tates of America (USA), Latin America, and Europe showing that
hese newly developed rotavirus vaccines were highly efficacious
nd safe in preventing severe rotavirus gastroenteritis lead to the
orld Health Organization (WHO) recommendation in 2006 that
accines against rotavirus be introduced into the national immu-
ization programmes of countries in regions where clinical trial
ata are available.
In 2009, following additional clinical trials in low income
ountries and the availability of post-marketing data from early
ntroducing countries in the Americas, Europe, and Australia, WHO
xtended its recommendation to include rotavirus vaccines in
he routine immunization programs in all countries globally and
articularly those countries with high child mortality due to diar-
hea. Following further analysis, in 2013 the WHO  recommended
hat all countries consider immunization along with the primary
 The findings and conclusions in this report are those of the authors and do not
ecessarily represent the official position of the Centers for Disease Control and
revention.
∗ Corresponding author.
E-mail address: gkang@cmcvellore.ac.in (G. Kang).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.029
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC B BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
immunization series at whatever age the series is administered [3].
Since 2006, over 50 countries have introduced rotavirus vaccine
into their national immunization programs.
Of the estimated 453,000 annual deaths due to rotavirus diar-
rhea in children <5 years of age globally, approximately 99,000
(22%), occur in Indian children [4] (Fig. 1). In addition, rotavirus is a
significant cause of childhood morbidity in India and is estimated to
account for approximately 457,000–884,000 hospitalizations and 2
million outpatient clinic visits each year, incurring health care costs
of Rs. 2.0–3.4 billion (US$ 41–72 million) annually [5]. Thus, the
potential health and economic impact of a national rotavirus vacci-
nation programme in India is immense. In addition to having both
internationally licensed vaccines in the market, Indian manufactur-
ers are developing several candidate rotavirus vaccines. The most
advanced of these vaccines is a candidate based on the indigenous
116E strain, a natural reasssortant of the human rotavirus G9P[11]
strain with the VP4 protein from a bovine rotavirus strain, that was
isolated from a neonate with an asymptomatic infection in Delhi
(Table 1). This vaccine has undergone a phase III clinical trial at
three centres in India (Delhi, Pune, and Vellore) and results from
this trial indicate efficacy at least equivalent to licensed vaccines in
developing countries [6].
While rotavirus vaccines are not currently recommended or
used in the national immunization programme in India, their use
has been included in the Indian Academy of Paediatrics guide-
lines for immunization. Widespread experience with rotavirus
vaccines under conditions of routine use in many countries
worldwide coupled with clinical trial data provide much insight
into the performance, impact, safety, and cost-effectiveness of
rotavirus vaccines. The objective of this paper is to review data
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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CFig. 1. Rotavirus disease burden globally and in India.
rom international settings to help address key questions regard-
ng anticipated rotavirus vaccine performance and impact in
ndia.
. Pre-licensure efficacy of rotavirus vaccines
Both internationally licensed rotavirus vaccines, RV1 and RV5,
ere found to be highly efficacious in clinical trials conducted in
he USA, Latin America, Europe, and high income Asian countries
Table 2). RV1 was 85% (95% CI: 71–83%) efficacious in preventing
evere rotavirus gastroenteritis (Vesikari score ≥11) among Latin
merican infants [1]. In subsequent trials examining efficacy during
he first two years of life, RV1 was 81% (95% CI: 71–87%) efficacious
gainst severe rotavirus gastroenteritis in Latin American children,
0% (95% CI: 85–94%) efficacious in European children, and 96%
95% CI: 85–100%) efficacious in children in high income Asian
ountries [7–9]. Similarly, in clinical trials conducted mainly in the
SA and Finland, RV5 was 96% (95% CI: 91–98%) efficacious against
ospitalizations due to rotavirus gastroenteritis caused by G1–G4
trains, 94% (95% CI: 89–97%) against emergency department visits,
nd 86% (95% CI: 74–93%) against office visits [2].
Because live oral vaccines, including earlier candidate rotavirus
accines, have a history of performing less well in developing
ountries [10–17], WHO  specifically recommended that efficacy
rials of both RV1 and RV5 be conducted in low income countries
f Africa and Asia before issuing a global recommendation for
otavirus vaccine use. Vaccine efficacy was modest in these trials.
n Africa (South Africa and Malawi), two doses of RV1 adminis-
ered at 10 and 14 weeks of age had 59% (95% CI: 36–74%) efficacy
gainst severe rotavirus diarrhea during the first year of life and
hree doses at 6, 10, and 14 weeks of age had 64% (95% CI: 42–78%)
fficacy [18]. Efficacy appeared to decline during the second year
f life, particularly among 2 dose recipients.
able 1
haracteristics of rotavirus vaccines.
RV1 RV5 
Manufacturer GlaxoSmithKline: Rixensart,
Belgium (Rotarix®)
Merc
(Rota
Parent  Strain Human rotavirus strain 89–12,
type G1P1A[8]
Bovin
type G
Formulation No reassortants 5 reas
G2xW
P1A[8
Dosing Regimen 2 oral doses, given with DTP
doses 1 and 2
3 oral
Status International Use Intern (2014) A171–A178
In Malawi, efficacy was  similar for two  and three dose recipients
during the first year of life (49% (95% CI: 11–72%) and 50% (95% CI:
11–72%), respectively) [18,19]. However, in the second year of life,
efficacy disappeared in two dose recipients (3% (95% CI: −101 to
53%)) while declining to 33% (95% CI: −49 to 71%) among three dose
recipients [18,19]. In South Africa, efficacy was similar in the three
dose recipients during the first year of life (82% (95% CI: 55–94%))
and overall during the first two  years of life (85% (95% CI: 35–98%))
[18,20]. However, among two  dose recipients, the study observed
a notable decline from 72% (95% CI: 40–88%) during the first year
to 32% (95% CI: −71 to 75%) over the first two  years of life [18,20].
For RV1, the two dose schedule was given at 10 and 14 weeks
of age. No efficacy data for RV1 with the recommended 6 and 10
week schedule is available, and it is possible that the efficacy may
be lower than that observed with the 10 and 14 week schedule due
to higher maternal antibody and potential interference by first oral
polio vaccine dose. The efficacy of three doses of RV5 administered
at 6, 10, and 14 weeks of age in Africa (Ghana, Kenya, and Mali) was
64% (95% CI: 40–79%) and in Asia (Bangladesh and Vietnam) was
51% (95% CI: 13–73%) against severe rotavirus disease during the
first year of life [21,22]. As seen for RV1, RV5 efficacy appeared to
decline during the second year of life and was  20% (95% CI: −16 to
44%) in Africa and 46% (95% CI: 1–71%) in Asia [21,22].
Despite lower efficacy in low income countries, the signifi-
cant disease burden in these settings results in a greater absolute
number of rotavirus cases prevented per 100 vaccinated children
compared with higher income countries with lower disease bur-
den. In clinical trials, RV1 efficacy during the first year of life in
South Africa (77%) was  higher than in Malawi (49%) but the vac-
cine prevented seven episodes of severe rotavirus gastroenteritis
per 100 vaccinated infants in Malawi compared with four episodes
prevented per 100 vaccinated infants in South Africa due to the
higher disease burden in Malawi compared with South Africa [18].
3. Post-licensure effectiveness and impact of rotavirus
vaccines
Rotavirus vaccines have had a notable impact on mortality, hos-
pitalizations and outpatient visits in countries that have introduced
the vaccine into their national immunization programme, includ-
ing some evidence suggesting that rotavirus vaccines may  offer
indirect protection to older, unvaccinated age groups. Perhaps the
most exciting post-licensure data pertains to the effect of rotavirus
vaccination in reducing deaths from childhood diarrhea in some
countries in Latin America, as the mortality benefits of vaccination
were not assessed in pre-licensure trials. In Mexico, following RV1
introduction into the national immunization programme in 2007,
the diarrhea mortality rate declined to 35% (95% CI: 29–39%) in 2008
compared with the pre-vaccine baseline (2003–2006): the decline
in mortality has been sustained for three years from 2008 to 2010
[23,24].
116E
k: Pennsylvania, USA
teq®)
Bharat Biotech International Limited:
Hyderabad, India
e rotavirus strain WC3,
6P7 [5]
Human rotavirus virus G9P[11] strain
of the Wa  genogroup with a bovine
rotavirus strain of genotype P[11]
sortants G1xWC3,
C3, G3xWC3, G4xWC3,
]xWC3
Natural reassortant
 doses, given with DTP 3 oral doses, given with DTP
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Table  2
Efficacy of rotavirus vaccines against severe rotavirus disease by year of life and country.
Vaccine Schedule Efficacy (95%
CI)—1st year of life
Efficacy (95% CI)—2nd
year of life
Overall Efficacy
(95% CI)—1st two
years of life
References
High and Middle Income
Settings
Latin America RV1 2, 4 months 83% (67%, 92%) 79% (66%, 87%) 81% (71%, 87%) [7]
Europe RV1 3, 5 months 96% (90%, 99%) 86% (76%, 92%) 90% (85%, 94%) [8]
Asia RV1 3, 5 months – – 96% (85%, 100%) [9]
US and Finland RV5 2, 4, 6 months 98% (88%, 100%) – – [2]
Low Income Settings
South Africa RV1 10, 14 weeks 72% (40%, 88%) – 32% (−71%, 75%) [18,20]
South Africa RV1 6, 10, 14 weeks 82% (55%, 94%) – 85% (35%, 98%) [18,20]
Malawi RV1 10, 14 weeks 49% (11%, 72%) 3% (−101%, 53%) 34% (−2%, 58%) [18,19]
Malawi RV1 6, 10, 14 weeks 50% (11%, 72%) 33% (−49%, 71%) 42% (9%, 64%) [18,19]
Africa (Ghana, Kenya,
Mali)
RV5 6, 10, 14 weeks 64% (40%, 79%) 20% (−16%, 44%) 39% (19%, 55%) [21]
Ghana RV5 6, 10, 14 weeks 65% (36%, 82%) 29% (−65%, 71%) 56% (28%, 73%) [21]
Kenya RV5 6, 10, 14 weeks 83% (26%, 98%) −55% (−1753%, 82%) 64% (−6%, 90%) [21]
Mali RV5 6, 10, 14 weeks 1% (−432%, 82%) 19% (−23%, 47%) 18% (−23%, 45%) [21]
Asia (Vietnam, RV5 6, 10, 14 weeks 51% (13%, 73%) 46% (1%, 71%) 48% (22%, 66%) [22]
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Vietnam RV5 6, 10, 14 weeks 72% (−
Bangladesh RV5 6, 10, 14 weeks 46% (−
Brazil saw a similar decline of 22–41% in diarrhea mortality rates
mong children <5 years of age following the introduction of RV1
nto the national immunization program in 2006 [25,26] (Fig. 2).
hile these were ecological analyses that could be affected by sec-
lar trends and failed to measure the specific reason for decline in
otavirus deaths (because the cause of diarrhea is rarely diagnosed
or deaths), the dramatic decline in mortality seen after vaccine
ntroduction, particularly during the winter seasonal months when
otavirus circulates, support the role of the vaccine.
Many middle and high income countries have observed substan-
ial declines of 17–55% in all-cause gastroenteritis hospitalization
nd even larger declines of 49–89% in rotavirus gastroenteritis hos-
italizations among children <5 years of age within the first two
ears following rotavirus vaccine introduction [25,27–42]. Due to
he large rotavirus disease burden among hospitalized children,
hese declines translate into large numbers of hospitalizations
revented. For example, studies show that in the USA follow-
ng the introduction of rotavirus vaccine in 2006 an estimated
0,000–60,000 acute gastroenteritis hospitalizations, or approxi-
ately 4–5% of all hospitalizations among US children <5 years of
ge, were prevented in 2008 [33] (Table 3).
Fig. 2. Reductions in all-cause diarrhea mortality rates among children <5 years7%) 65% (−48%, 94%) 64% (8%, 91%) [22]
%) 39% (−18%, 70%) 43% (10%, 64%) [22]
In some settings, researchers have observed the indirect effects
of rotavirus vaccines among children age-eligible but missed by the
vaccination program, and among older children and adults. The USA
observed declines of 6–46% in rotavirus gastroenteritis hospital-
izations among age-eligible unvaccinated children although these
declines were smaller than the 88–93% decline observed among
age-eligible vaccinated children [42]. Many countries including the
USA and Belgium have observed declines in rotavirus disease dur-
ing the first few years of vaccine introduction that exceed the
coverage levels of rotavirus vaccine in the population [43–46]. Fur-
thermore, the declines in rotavirus hospitalizations among children
<5 years of age that were age-ineligible during the first few years
after vaccine introduction saw declines in rotavirus gastroenteri-
tis hospitalizations (24–81%) that were similar to or slightly lower
than those declines observed among vaccine-eligible age groups
(50–96%) [27–29,31,32,34,35,38,40,43,47]. Additionally, studies in
the USA observed declines in acute gastroenteritis hospitalizations
of 8–29% among older children and adults 5–24 years of age during
the rotavirus season following rotavirus vaccine introduction sug-
gesting an unappreciated burden of rotavirus disease in these older
populations [48].
 of age pre- and post-rotavirus vaccine introduction in Mexico and Brazil.
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Table  3
Impact of national rotavirus vaccine introduction on all-cause and rotavirus diarrhea hospitalizations in children <5 years of age.
Country Vaccine (Year
Introduced)
Post-Vaccine
Years Studied
Percent reduction in specified hospitalizations
among children <5 years of age
Impact Reference
All-Cause Diarrhea
Hospitalizations
Rotavirus Hospitalizations
Brazil RV1 (2006) 2007–2009 17% – 40,000 diarrheal hospital admissions in
children <5 years age averted annually
[25]
El Salvador RV1 (2006) 2008–2009 28–37%a 69–81% Annual healthcare visits for diarrhea
(inpatient and outpatient) among
children <5 years of age decreased by
61,000 in 2008 and 46,000 in 2009
[28]‡
Mexico RV1 (2006) 2008–2009 11–40%b – 16,000 diarrhea hospitalizations in
children <5 years of age averted
annually; 1 hospitalization prevented
per 125 vaccinated infants by 5 years
of age
[80]
USA RV5 (2006)
RV1(2008)
2008–2009 31–33% 62–71%c 38,000 diarrheal hospitalizations in
children <5 years age averted annually
[76]
‡ Study period July 2007–June 2009.
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b During peak rotavirus season.
c Rotavirus-coded hospitalizations.
. Strain diversity
Rotavirus strains are characterized by two surface proteins, VP7,
he glycoprotein (G protein) and VP4, the protease-cleaved protein
P protein), that evoke antibody response. At least 10 G and 11 P
ntigen types have been identified among human rotavirus strains
ith five strains (G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8]) found
o be responsible for the majority of severe rotavirus infections
orldwide [49–51]. However, there are extensive differences in the
redominant circulating strains between geographic regions and
hange over time [51]. G1 strains predominated globally from 1996
o 2007 although the relative frequency decreased over time [51].
onversely, in Southeast Asia, G2 strains were predominant during
996–1999, G9 strains dramatically emerged in 2000–2003, and G1
nd G2 strains predominated from 2004 to 2007 accompanied by
he emergence of G12 strains [51].
Clinical trials of RV1 in Latin America found high efficacy (91%;
5% CI: 71–98%) against severe (Vesikari score ≥11) rotavirus gas-
roenteritis due to G1P [8] but lower, non-significant efficacy (45%;
5% CI: −82 to 86%) against G2P [4,1]. However, a subsequent trial
n Europe with a larger sample size showed high levels of protec-
ion against severe rotavirus gastroenteritis due to G1 (96%; 95%
I: 90–99%) and G2 strains (86%; 95% CI: 24–99%) as well as G3
94%; 95% CI: 53–100%), G4 (95%; 95% CI: 68–100%), and G9 strains
85%; 95% CI: 72–93%) [8]. The RV1 clinical trials in Africa showed
imilar efficacy against G1 strains (64%; 95% CI: 30–82%) and non-
1 strains (60%; 95% CI: 37–74%) [18]. The clinical trial of RV5 in
he USA and Finland observed a 95% (95% CI: 92–97%) rate reduc-
ion in the number of hospitalizations and emergency department
isits due to G1 strains and rate reductions of 93% (95% CI: 49–99%),
9% (95% CI: 52–98%), and 100% (95% CI: 67–100%) in the num-
er of hospitalizations and emergency department visits due to G3,
4, and G9 strains, respectively [2]. The RV5 clinical trial in Africa
rovided significant protection against severe gastroenteritis due
o G8 strains (88%; 95% CI: 7–100%), P1A[8] strains (36%; 95% CI:
–58%), and P2A[6] strains (48%; 95% CI: 10–70%) [21]. In the RV5
linical trial in Asia, strain-specific vaccine efficacy estimates were
mprecise due to small numbers and the trial observed significant
rotection only against P1A[8] strains (50%; 95% CI: 19–69%) [22].
Strain-specific vaccine efficacy estimates from the clinical trialsre limited to the predominately circulating strains at the time of
he trials. However, post-licensure vaccine effectiveness data from
ountries that have introduced rotavirus vaccine into their rou-
ine immunization programs have enabled vaccine performanceagainst a variety of strains in a variety of settings to be evaluated.
Of particular interest has been the apparent emergence of G2P[4]
in Brazil and Australia following the introduction of RV1 in these
countries [52,53]. G2P[4] is fully heterotypic compared to the RV1
strain and there was some concern that the selective pressure of
the vaccine may  have led to its predominance. However, vaccine
effectiveness studies in Brazil found that RV1 was 39–89% effec-
tive against severe disease caused by G2P[4] strains although the
effectiveness may  wane in children >12 months of age [36,54,55].
RV1 was 83–85% effective against rotavirus gastroenteritis due to
G2P[4] in children 6–11 months of age in Brazil but only 5–41%
effective in children ≥12 months of age [54]. Similarly, a study
among indigenous children <3 years of age in Australia noted wan-
ing vaccine effectiveness, where RV1 was  19% (95% CI: −105 to 68%)
effective in preventing rotavirus hospitalizations among children
<3 years of age during an outbreak of G2P[4] with higher vaccine
effectiveness in children <1 year of age (51%; 95% CI: −92 to 88%)
than in children 1–2 years of age (9%; 95% CI: −283 to 79%) [56].
An earlier study in the same indigenous population found that RV1
was 85% (95% CI: 23–97%) effective against rotavirus hospitaliza-
tion when G9P[8] was the predominantly circulating strain [57].
RV1 has also been shown to be effective in El Salvador (76%; 95%
CI: 64[8] was the predominantly circulating strain and in Mexico
(94%; 95% CI: 16–100%) against G9P [4,58,59].
Post-licensure vaccine effectiveness studies have also shown
RV5 to offer protection against several different strains. A study
in the USA showed RV5 was  95% (95% CI: 57–99%) effective against
hospitalizations and emergency department visits due to G3P[8,60]
Another study in USA found that RV5 was 83–96% effective against
G1, G3, G9, and G12 strains and 72–77% effective against G2 strains
[61]. In Nicaragua, RV5 was  51% (95% CI: 23–69%) effective against
G2P[4] rotavirus disease resulting in hospitalization or intravenous
rehydration, 65% (95% CI: 39–80%) against severe (Vesikari score
≥11) G2P[4] rotavirus disease, and 82% (95% CI: 47–94%) against
very severe (Vesikari score ≥15) G2P[4] rotavirus disease [62].
5. Vaccine safety
A previous quadrivalent rhesus-reassortant rotavirus vaccine,
RotaShield® manufactured by Wyeth and licensed in 1998, was
withdrawn from use in the USA in 1999 after it was associated
with an increased risk of intussusception, a rare adverse event in
which one portion of the bowel telescopes into another [63–65].
Researchers in the USA observed an excess risk of one case of
T.S. Rao et al. / Vaccine 32S (2014) A171–A178 A175
Table  4
Benefit-risk analyses for selected countries with national rotavirus vaccination programs.
Rotavirus Hospitalizations
(Deaths) Prevented
Intussusception
(Deaths) Caused
Reference
Mexico 11,600 (663) 41 (2) [67]
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iBrazil 69,600 (640) 
Australia 6,500 (0) 
United States 53,000 (14) 
ntussusception per 10,000 infants vaccinated with RotaShield [66].
ubsequently the USA conducted large clinical trials of for RV1 and
V5 among 60,000–70,000 infants to detect a risk of intussuscep-
ion similar to that observed with RotaShield [1,2]. Trials failed to
etect an increased risk of intussusception following rotavirus vac-
ination within 30 days of either dose of RV1 or 42 days after any
f the RV5 doses [1,2]. However, post-marketing surveillance has
etected a small increased risk of intussusception (1–2 excess cases
er 100,000 infants vaccinated) in the first week following the first
ose of vaccine in some populations but not in others [67–72].
Assessment analyses have found favorable benefit-risk ratios in
ountries with inconclusive rotavirus vaccine efficacy (Table 4).
 self-controlled case series analysis observed a short term
isk of intussusception of one excess case of intussusception
er 51,000–68,000 infants vaccinated in the 1–7 days following
otavirus vaccination in Mexico and Brazil [67]. Both of these
ountries documented significant declines in all-cause diarrhea
eaths in children following the introduction of rotavirus vaccine
23–26]. For example, each year in Mexico, the rotavirus vaccine
ill avert an estimated 663 deaths and 11,551 hospitalizations due
o rotavirus among children <5 years of age and cause 2 excess
eaths (approximately 1 for every 1 million vaccinated infants) and
1 excess hospitalizations (approximately 1 for every 51,000 vac-
inated infants) for intussusception [67]. Similarly, in Brazil, the
otavirus vaccine will avert an estimated 640 deaths and 69,572
ospitalizations due to rotavirus among children <5 years of age
nnually and cause 3 excess deaths (approximately 1 for every 1.4
illion vaccinated infants) and 55 excess hospitalizations (approx-
mately 1 for every 68,000 vaccinated infants) for intussusception
67].
. Cost-effectiveness of a rotavirus vaccination program
Global, regional, and country-specific studies have found
otavirus vaccine to be a cost effective intervention. Globally,
otavirus vaccine will prevent an estimated 180,000 rotavirus
eaths in children <5 years of age annually when introduced
nto the national immunization programmes of all GAVI-eligible
ountries [73]. The estimated cost per disability adjusted life year
DALY) averted is US$ 42 for all GAVI-eligible countries and US$
0 for GAVI-eligible countries located in Southeast Asia [73]. For
very 1000 children vaccinated against rotavirus in GAVI-eligible
ountries in Southeast Asia, an estimated 52 DALYs will be averted,
7 health care visits due to rotavirus diarrhea will be prevented,
nd US$ 1360 in medical costs will be saved [73]. Two  indepen-
ent analyses in India concluded that the introduction of rotavirus
accines into the routine, national immunization program in India
ould be cost-effective [74,75]. At a price of US$ 7.00 per dose,
he initial price per dose of vaccine, these models estimated an
ncremental cost effectiveness ratio (ICER) of US$ 174 per life years
aved and US$ 134–200 per DALY averted, which satisfies the WHO
riterion for a cost effective intervention where the incremental
ost-effectiveness ratio is less than the country’s per capita gross
omestic product [74,75]. At the more likely cost of US$ 1.00 per
ose in India, the ICER is US$ 21 per DALY averted [74]. At current
mmunization levels a national rotavirus vaccination programme in55 (3) [67]
14 (0) [68,81]
58 (0.2) [76]
India would prevent 41,000–44,000 deaths and 203,000–293,000
hospitalizations due to rotavirus among children <5 years of age
[74,75].
Studies have observed that following the introduction of
rotavirus vaccine into national immunization programs, there are
declines in annual costs to treat rotavirus disease associated with
declines in medical visits. After rotavirus vaccine was introduced
into the national immunization program in the USA in 2006, one
study found that almost 65,000 hospitalizations due to rotavirus
among children <5 years of age over the following two  years from
July 2007 to June 2009 were prevented which saved approxi-
mately US$ 278 million in treatment costs [42]. Another USA study
estimated that the vaccine could prevent 53,000 hospitalizations
due to rotavirus among children <5 years of age [76]. Addition-
ally, a study examining the indirect benefits of rotavirus vaccine
in older children and young adults, a study in the USA estimated
that approximately 8800 gastroenteritis hospitalizations were pre-
vented among individuals 5–24 years of age in 2008 saving US$ 42
million in treatment costs [48].
7. Lessons for India
The dramatic declines in rotavirus disease documented in mid-
dle and high income countries following vaccine introduction,
coupled with the high disease burden in low income countries like
India suggest that large declines in the number of deaths, hospi-
talizations, and outpatient visits due to rotavirus gastroenteritis
may  be observed following vaccine introduction into the national
immunization programs despite modest vaccine efficacy. [5] Thus,
with the high rotavirus disease burden in India, rotavirus vaccines
have substantial potential to prevent a large number of deaths,
hospitalizations, and outpatient visits due to rotavirus even with
the modest efficacy. Data on rotavirus vaccine impact in develop-
ing countries are sparse due to limited use of rotavirus vaccines in
these countries. This will change in the coming years with GAVI
support and increased use of vaccines in developing countries. But
it is important that Indian policy makers consider available data as
early as possible.
The benefits of rotavirus vaccination may extend beyond those
which are expected among children <5 years of age. Indirect bene-
fits of rotavirus vaccination have been observed in the early years of
the rotavirus vaccination program in early adopter countries sug-
gesting that rotavirus vaccine may  offer some protection to those
populations not directly covered by the immunization program.
Little information is available about the incidence of rotavirus dis-
ease among older children and adults in most countries, including
in India, but even if a small unrecognized disease burden exists
in these populations, the impact of rotavirus vaccines at the pop-
ulation level could be greater than anticipated. Further studies
of disease burden among all ages and data from clinical trials or
demonstration projects in India will help to determine the perfor-
mance and project the impact of rotavirus vaccine introduction.India, like other developing countries, has documented tremen-
dous diversity in circulating rotavirus strains [77–79] (Fig. 3).
Fortunately, substantial evidence suggests that rotavirus vaccines
provide heterotypic protection against a wide range of genotypes.
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ecular trends in circulating strains continue to occur in countries
hat have introduced rotavirus vaccine. While it may  be too soon
o determine if vaccine pressure will result in the emergence of
scape strains, both globally available vaccines have demonstrated
ffectiveness against multiple rotavirus strains. Countries that have
ntroduced rotavirus vaccine, such as Brazil, Mexico, Australia, and
he USA, have documented large declines in hospitalizations due
o rotavirus disease further suggesting that these vaccines are hav-
ng an impact on rotavirus disease burden due to a variety of
trains. However, small differences in effectiveness against indi-
idual strains may  lead to the emergence of escape strains over
ime making continued monitoring of circulating strains important
ollowing vaccine introduction.
Risk-benefit analyses in several countries that have introduced
otavirus vaccine into their national immunization programs have
ound that the benefits of rotavirus vaccination greatly outweigh
he risk. While the analyses are country-specific and vaccine-
pecific, countries like India with high rotavirus mortality burden
ill likely benefit from the introduction of rotavirus vaccine even if
here is a low level risk of intussusception. However, each country
ust weigh its own benefit-risk scenario prior to vaccine introduc-
ion.
. Summary
India has its own rotavirus vaccines in the pipeline with phase
 trials of the 116E vaccine completed and those of other can-
idates expected to start soon. Once this vaccine is available for
se in India and as other vaccines become available, many issues
ncluding performance and impact under conditions of routine use,
ffectiveness against currently circulating strains, safety, and cost-
ffectiveness will need to be examined. However, the experience of
he international community with the two currently available oral
otavirus vaccines does provide insight into the likely performance
nd impact of the Indian 116E vaccine. Due to the high rotavirus
ortality burden, the introduction of a vaccine will likely have a
otable impact on disease burden, protect against a wide variety of
irculating strains, and result in a decrease in the economic burden
f rotavirus in India. Studies to examine rotavirus vaccine impact
nd safety using many of the study designs employed by interna-
ional researchers can help answer many of these questions and
rovide support for sustained use of rotavirus vaccine in India.
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